TACE induces tumor heterogeneity and a pro-inflammatory microenvironment, with elevated interactions between NABP1+ malignant hepatocytes, neutrophils, and CD8+ T cells linked to poor prognosis. NABP1 emerges as a potential biomarker for identifying HCC patients likely to respond to TACE. Here, CD8A is linked to neoplasm.